- Psyence Group (PSYG) has provided an update on its three strategic focus areas
- Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization
- ISO22000 certified commercial psilocybin production facility and lab upgraded
- GOODMIND™, functional mushroom product, launched online and in-store
- The company completed a C$1.273 million private placement
Psyence Group (PSYG) has provided an update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.
Highlights:
- Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament Health
- Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
- ISO22000 certified commercial psilocybin production facility and lab upgraded
- Received an import permit from Health Canada on behalf of Psilo Scientific
- GOODMIND™, functional mushroom product, launched online and in-store, sale through 300 stores of one of Africa’s largest coffee retail chains
- Previously announced C$1.273 million private placement being closed
- Exploring capital market initiatives in UK, hires Investment Bank
Psyence CEO Dr. Neil Maresky, sat down with Coreena Robertson to discuss the update.
Psyence is a life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Psysence Group Inc. (PSYG) opened trading at C$0.085 per share.